## **Core Concept**
Levodopa is a precursor to neurotransmitters like dopamine, and its combination with carbidopa is a cornerstone in the treatment of Parkinson's disease. This combination aims to increase the availability of levodopa in the brain by inhibiting its peripheral conversion to dopamine.

## **Why the Correct Answer is Right**
The correct answer involves understanding the mechanism of action of levodopa and carbidopa. Levodopa crosses the blood-brain barrier to increase dopamine levels in the brain, which helps alleviate symptoms of Parkinson's disease. However, when administered alone, a significant portion of levodopa is converted to dopamine peripherally by the enzyme dopa-decarboxylase (also known as aromatic L-amino acid decarboxylase), which reduces its availability to cross the blood-brain barrier and limits its therapeutic efficacy. Carbidopa inhibits this peripheral conversion, thereby increasing the amount of levodopa that reaches the brain.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not accurately represent the primary reason for combining levodopa with carbidopa.
- **Option B:** This option is incorrect as it does not specify the correct mechanism or purpose of combining these two drugs.
- **Option D:** This option is incorrect because it does not accurately describe the role of carbidopa in the treatment of Parkinson's disease.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the combination of levodopa and carbidopa is used to manage symptoms of Parkinson's disease by effectively increasing dopamine levels in the brain while minimizing peripheral side effects. This combination does not cure Parkinson's disease but significantly improves the quality of life for patients.

## **Correct Answer:** . To decrease peripheral conversion of levodopa to dopamine.